Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04938492
Other study ID # STUDY00005387
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 12, 2021
Est. completion date July 1, 2023

Study information

Verified date August 2023
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study will determine if cognitive behavioral therapy will help improve loneliness in people who use opioids.


Description:

The proposed study will be the first to assess the cognitive, affective, and behavioral pathways by which loneliness impacts opioid use. Individuals with an opioid use disorder (OUD) reporting loneliness will be randomized to either a 6-session Cognitive- Behavioral Therapy for loneliness (CBT-L) or a 6-session education control condition, both delivered via telehealth. Telehealth delivery can be easily implemented and can increase reach and access to individuals not engaged in treatment. We will use an established brief CBT manual to address loneliness. We will assess loneliness, negative affect (i.e., depression and anxiety), and the quality and quantity of social interactions prior to, during, and after the intervention to evaluate the subsequent impact on opioid use trajectories. Participant will complete questionnaires pre-treatment, post-treatment, and at 1- and 2-months posttreatment.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date July 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Must be ages 18+ - Understand English - Have internet access - Screen positive for an active OUD on the OUD Module of the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV) - Screen positive for loneliness by scoring at least a T-score > 60 on the NIH Toolbox Loneliness Scale Exclusion Criteria: - Consistent with previously used telehealth-delivered assessments, we will exclude any participant with cognitive impairment as measured by the Blessed Orientation-Memory-Concentration Test (BOMC) - Potential participants who are in the process of detoxifying as measured by the Subjective Opiate Withdrawal Scale will also be excluded

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavioral Therapy for loneliness (CBT-L)
6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
Physical Health Education Training (PHET)
Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.

Locations

Country Name City State
United States University of Rochester Medical Center Rochester New York

Sponsors (2)

Lead Sponsor Collaborator
University of Rochester National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in loneliness Loneliness will be measured using the UCLA Loneliness Scale. A 20-item scale designed to measure one's subjective feelings of loneliness as well as feelings of social isolation. Participants rate each item as 1 (never), 2 (rarely), 3 (sometimes) or 4 (often). The scores range from 20-80 with higher scores indicating worse outcome. baseline to 2 months
Secondary Mean change in number of days of opioid use Participants will complete a calendar indicating the type and frequency of drug use. baseline to 2 months
Secondary Mean change in percent days abstinent Participants will complete a calendar indicating the type and frequency of drug use. baseline to 2 months
Secondary Mean change in social interactions Duke Social Support Index assesses several domains of perceived social support, including social network size, social interaction, social satisfaction, and instrumental social support. Higher scores indicate a higher quality of social interactions. Scores range from 0 to 37. baseline to 2 months
Secondary Mean change in depression Depression will be measured using the PROMIS tool. The scores range from 4-20 with higher scores indicating worse outcome. baseline to 2 months
Secondary Mean change in anxiety Anxiety will be measured using the PROMIS tool. The scores range from 4-20 with higher scores indicating worse outcome. baseline to 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT04095624 - Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion N/A
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT04598074 - Opioid Package Prototype (OPP) N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT03570320 - Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries? N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Recruiting NCT05877157 - Pain AND Opioids After Surgery
Recruiting NCT06055205 - A Pain and Coordination Plan for Reduced Opioid Use After Accidental Injuries N/A
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT04868552 - Naloxone Education in Total Joint Patients N/A
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Terminated NCT06217380 - Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program N/A
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Terminated NCT03426137 - Relieving Acute Pain (RAP) Study: A Pilot Study Phase 2